Project ALS is pleased to share that the FDA has approved the drug edaravone – the first approved ALS treatment in over 20 years.
Edaravone, a free radical scavenger, appears to react with nerve-damaging compounds generated as part of the disease process. After six months of treatment, on top of standard-of-care, data showed the intravenous drug reduced the rate of functional decline in patients by about a third.
Motor neurons project out to the muscles in our limbs to drive muscle contraction, allowing us to speak, breathe, and move. These cells are housed